• Skip to main content
  • Skip to footer

Akari Therapeutics

AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE

Menu
  • HOME
  • ABOUT
    • Close
    • COMPANY OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • CEO CORNER
    • SCIENTIFIC ADVISORY BOARD
  • AREAS OF FOCUS
    • Close
    • PIPELINE
    • POSTERS & PUBLICATIONS
    • LEGACY PIPELINE ASSETS
  • INVESTOR RELATIONS
    • Close
    • OVERVIEW
    • GENERAL MEETING
    • CORPORATE GOVERNANCE
      • Close
      • GOVERNANCE OVERVIEW
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIAL INFORMATION
      • Close
      • SEC FILINGS
      • ANNUAL REPORTS
    • NEWS & PRESENTATIONS
      • Close
      • PRESS RELEASES
      • PRESENTATIONS
    • ANALYST COVERAGE
    • STOCK INFORMATION
      • Close
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
    • EMAIL ALERTS
  • PRESS
    • Close
    • PRESS RELEASES
    • STORIES
  • CONTACT US

Akari TX / June 25, 2019

Change of AGM Venue on June 27, 2019

Dear Shareholder,

We would like to inform shareholders that we shall be unable to hold our forthcoming Annual General Meeting at the place stated in the notice of that meeting, Chandos House, 2 Queen Anne Street W1G 9LQ, on account of recent water damage there.  The Board therefore proposes to commence the meeting there at the scheduled time of 2.00 p.m., local time, on June 27, 2019, for the sole purpose of immediately adjourning it to 1 Wimpole Street, London, W1G 0AE (CUHK meeting room), a short distance away, at 2.15 p.m. (or as soon thereafter as is practicable), local time, on the same day.  Shareholders are therefore invited to join us, in person or by proxy, at 2.15 p.m. on June 27 at 1 Wimpole Street, London, W1G 0AE. 

The business to be conducted at the meeting remains as set out in the notice of meeting and no other changes to the procedures for voting at and attending the meeting are proposed.  There will be no effect on voting instructions already given by way of proxy card or through a depositary or other intermediary, which will remain valid.

On behalf of the Board of Directors of
Akari Therapeutics, Plc,
Ray Prudo
Executive Chairman
June 25, 2019

Filed Under: Press Release

Footer

Follow Us

Terms of Use
Privacy Statement
Contact Us

Akari TX

Copyright © 2025 · Akari Therapeutics · Site Designed by Polus Digital, Inc.